日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

  Home>News Center>China
       
 

European drug maker gives up patent
By Qin Jize (China Daily)
Updated: 2004-08-19 00:45

Europe's largest drug maker GlaxoSmithKline (GSK) has abandoned its defence of a patent in China for rosiglitazone, a major chemical component of its leading anti-diabetes drug Avandia.

The move was announced during a preliminary hearing over the patent challenge held by State Intellectual and Patent Office (SIPO) Wednesday.

"After careful assessment of the situation, GSK is voluntarily abandoning the rosiglitazone formulation patent and withdrawing from the hearing," said Lillian Xiao, spokeswoman of the Beijing-based office.

She emphasized that the patent that GSK is abandoning is not the Avandia compound patent covering rosiglitazone maleate.

In China, patents covering the active ingredient of Avandia and its manufacturing process were granted to GSK in 2000 and 1998 respectively.

However, starting from the early 1990s, more than a dozen Chinese drug makers began to copy rosiglitazone.

GSK filed the third patent application to SIPO in 1998 for pharmaceutical formulations containing 2 to 8 mg rosiglitazone or its pharmaceutically acceptable salts or solvates, which extends the protection for the product to the other salts of rosiglitzone.

The patent was granted in July 2003 and GSK immediately requested its Chinese rivals to stop copying rosiglitazone, otherwise they would face legal actions.

Early this year, four Chinese pharmaceuticals makers, including Shanghai Sunve Pharmaceutical Company and Chongqing-based Taiji Group filed invalidation requests against the rosiglitazone formulation patent granted to GSK.

A hearing had been scheduled Wednesday by the Patent Re-examination Board to consider these invalidity requests. But GSK quit the action.

Xiao said GSK's decision will not let Chinese competitors sell copies of Avandia, because the company still holds two other Chinese patents covering the drug.

"We're very pleased that the rosiglitazone formulation patent is no longer exist and GSK has made a reasonable decision," said Chen, official of the patent department with Taiji Group.

"It provides access to Chinese pharmaceutical makers," said Hou Dakun, a consultant for the pharmaceutical industry in China. "They now can produce a local variant Avandia after GSK waived its patent protection.

But he didn't think there would be an obvious increase of patent lawsuit challenging the international pharmaceutical giants because the "domestic enterprises are still weak in terms of research and development."

Few Chinese drug makers know how to produce the most advanced medicine even though the formulation patent is invalid, he said.

However, he added, any patent earning a huge profit in the market would spark heated disputes not only in China but all over the world. Drugmakers are becoming increasingly aware of breaking the monopoly of international pharmaceutical giants on compounds they are copying, he said.

The Chinese Government withdrew the patent last month for Viagra, the male-impotence treatment made by Pfizer Inc, the world's biggest drug maker.

Although the two parties to the lawsuit deny any links between Viagra and Avandia, the public still held the opinion that the Viagra ruling would no doubt influence the Avandia result.

"As an arbitration agency, we will always be just and fair," said Bai Guangqing, deputy director of the Patent Re-examination Board, under the SIPO.

He assured that the revoking of Viagra would not play any role if the Avandia case is investigated. "It's only evidence and investigation can tell the final result," he said.



 
  Today's Top News     Top China News
 

4,000 corrupt officials fled with US$50 billion

 

   
 

Government to raise taxable personal income

 

   
 

Natural disaster affects almost 13 million

 

   
 

Official gets death for stealing relics

 

   
 

China: US sending "wrong signal" to terrorists

 

   
 

China cracks down on "phone sex" services

 

   
  Government to raise taxable personal income
   
  4,000 corrupt officials fled with US$50 billion
   
  HK LegCo candidate arrested for taking prostitutes
   
  China to open wholesale market of publications
   
  Japanese snakehead deported from China
   
  Beijing highway boss to be arrested for bribe
   
 
  Go to Another Section  
 
 
  Story Tools  
   
  News Talk  
  When will china have direct elections?  
Advertisement
         
主站蜘蛛池模板: 在线观看视频色 | 精品一卡2卡三卡4卡免费视频 | 黄色a视频 | 久久影视一区 | 欧美www在线观看 | 日本久久精品 | 天天碰夜夜| 日韩精品极品视频在线观看免费 | 日日骚视频 | 亚洲aⅴ天堂av在线电影软件 | 成人免费久久精品国产片久久影院 | 免费国产va在线观看视频 | 欧美国产成人一区二区三区 | 成年网站在线观看 | 国产69久久久欧美黑人A片 | 国产毛片久久久久久国产毛片 | 91久久久久久久久久久 | 日韩国产欧美在线观看一区二区 | 亚洲国产视频一区 | 护士hd欧美free性xxxx | 99热久久这里只有精品6国产网 | 98色花堂国产第一页 | 中文字幕在线免费观看 | 亚洲精品成人 | 99精品视频3 | 草草久久久 | 日本黄色网址免费 | 青草视频网站在线观看 | 黄色片快播 | 伊人网综合 | 国产成人综合在线观看 | 午夜精品小视频 | 午夜色大片在线观看 | 美女下面直流白浆视频 | 被摁着灌浓精囚禁高h1v1 | 青青草视频免费观看 | 日本色网址 | 日韩在线 在线播放 | 久久首页 | 99视频久久精品久久 | 香蕉国产人午夜视频在线 |